New Study Results Presented at ASCO Supports DiviTum® for Monitoring Advanced Breast Cancer Treatment – Biovica International AB

STOCKHOLM, May 17, 2018 /PRNewswire/ — The EFECT-study evaluated standard hormonal therapies for women with advanced breast cancer and DiviTum® was used as a non-invasive tool for monitoring therapy response. 244 patients had blood samples analyzed with DiviTum® in a collaboration…

View more at https://www.prnewswire.com/news-releases/new-study-results-presented-at-asco-supports-divitum-for-monitoring-advanced-breast-cancer-treatment—biovica-international-ab-300650153.html

No Comments

No comments yet.

Sorry, the comment form is closed at this time.